Belvedere Trading
VERV

Belvedere Trading’s Verve Therapeutics VERV Stock Holding History

Belvedere Trading’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-121
Closed -$1.6K – 1023
2023
Q3 		$1.6K Buy
+121
New +$1.95K ﹤0.01% 592

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Belvedere Trading's VERV Position: Q4 2023 in Review

Belvedere Trading sold out of Verve Therapeutics (VERV) in Q4 2023, closing a stake of 121 shares — an estimated $1.6K sold.

Belvedere Trading first reported a position in VERV in Q3 2023 and held it in 1 quarter. The position peaked at $1.6K in Q3 2023. 157 funds tracked by Wall St. Rank hold VERV as of Q4 2023.

  • Belvedere Trading reported no remaining Verve Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Belvedere Trading sold 121 Verve Therapeutics shares in Q4 2023, an estimated $1.6K.
  • Belvedere Trading first reported a position in Verve Therapeutics in Q3 2023 and held it in 1 quarter.
  • Belvedere Trading's Verve Therapeutics position peaked at $1.6K in Q3 2023.
  • 157 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.